| dc.contributor.author | Scuccimarri, Rosie | |
| dc.contributor.author | Sutton, Evelyn | |
| dc.contributor.author | Fitzcharles, Mary-Ann | |
| dc.date.accessioned | 2020-04-09T04:21:42Z | |
| dc.date.available | 2020-04-09T04:21:42Z | |
| dc.date.issued | 2020-04 | |
| dc.identifier.uri | https://doi.org/10.3899/jrheum.200369 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/985 | |
| dc.description.abstract | Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Infectious Diseases | en_US |
| dc.subject | Hydroxychloroquine | en_US |
| dc.subject | Rheumatic Diseases | en_US |
| dc.subject | Ethics | en_US |
| dc.title | Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Ethical considerations for research | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | The Journal of Rheumatology | en_US |
